United States and Japan Lead 2025 Idiopathic Pulmonary Fibrosis Innovation with Clinical Trials and Biomarker Research | Top Companies are Roche Holdings AG, Boehringer Ingelheim GmbH, Genentech Inc.

The global idiopathic pulmonary fibrosis market size reached US$ 4.24 Billion in 2024 from US$ 3.96 Billion in 2023 and is expected to reach US$ 8.25 Billion by 2033, growing at a CAGR of 7.7% during the forecast period 2025-2033.

📌 Download your Exclusive Sample Report Today: (Corporate Email gets priority access):- https://datamintelligence.com/download-sample/idiopathic-pulmonary-fibrosis-market?kb

☛ Idiopathic Pulmonary Fibrosis Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In July 2025, Boehringer Ingelheim announced new clinical data on Ofev (nintedanib) demonstrating slowed lung function decline in early-stage IPF patients. The findings were presented at the American Thoracic Society (ATS) conference, reinforcing Ofev's leading role in IPF management.

✅ In June 2025, FibroGen initiated a Phase 2 trial for its novel oral antifibrotic agent targeting TGF-β pathways. The study aims to evaluate the drug's efficacy in reducing fibrosis progression among U.S. patients with moderate IPF.

✅ In May 2025, United Therapeutics collaborated with the Mayo Clinic to explore the potential of regenerative therapies in IPF treatment. The partnership will focus on lung tissue regeneration using stem cell-derived biologics.

Japan: Recent Industry Developments

✅ In July 2025, Shionogi & Co., Ltd. launched a nationwide study on biomarkers for early IPF detection. The project is part of Japan's precision medicine initiative and aims to improve patient outcomes through earlier diagnosis.

✅ In June 2025, Kyowa Kirin announced preclinical success with its small molecule inhibitor targeting fibroblast activation. The compound showed strong antifibrotic effects in animal models, paving the way for human trials.

✅ In May 2025, Chugai Pharmaceutical expanded its IPF research program with AI-assisted screening of novel drug candidates. The initiative supports the discovery of next-generation therapies that could halt or reverse fibrosis progression.

☛ Idiopathic Pulmonary Fibrosis Market: Drivers

The idiopathic pulmonary fibrosis (IPF) market is expanding due to the rising prevalence of chronic respiratory disorders and the growing elderly population worldwide. Increased exposure to environmental pollutants, smoking, and occupational hazards has also heightened disease incidence. Advances in diagnostic imaging and molecular biology are enabling early detection and better disease characterization. Pharmaceutical innovations, particularly in antifibrotic therapies, are enhancing treatment outcomes and patient survival rates. The growing demand for effective therapies is encouraging greater R&D investments by leading biopharmaceutical companies.

Growing awareness of interstitial lung diseases among healthcare professionals and patients is further driving early diagnosis and treatment adoption. Supportive government initiatives and the availability of reimbursement for IPF therapies are improving access to advanced medications. The emergence of precision medicine and biomarker-driven approaches is also transforming the therapeutic landscape. Collaborations between academic research institutions and pharmaceutical firms are accelerating drug discovery and clinical trials. With an increasing focus on personalized treatment and disease management, the idiopathic pulmonary fibrosis market is poised for sustained growth in the coming years.

☛ Idiopathic Pulmonary Fibrosis Market: Major Players

Roche Holdings AG, Boehringer Ingelheim GmbH, Genentech Inc., FibroGen Inc., Galapagos NV, MEDICINOVA INC., Bristol Myers Squibb Company, Biogen Inc., AstraZeneca PLC, and Novartis International AG.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/idiopathic-pulmonary-fibrosis-market?kb

☛ Segments Covered in the Idiopathic Pulmonary Fibrosis Market:

By Treatment: Drugs, Nintedanib, Pirfenidone, Oxygen Therapy, Pulmonary rehabilitation, Lung transplant.

By End-User: Hospitals, ASCs, Clinics and Others.

📌 Get Corporate Access to Live pulmonary fibrosis Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=idiopathic-pulmonary-fibrosis-market?kb

☛ Regional Analysis for Idiopathic Pulmonary Fibrosis Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.